A Survival Analysis of Invasive Breast Cancer Patients with and Without in Situ Neoplasm

Karim Atashgar¹, *, Ayeh Sheikhaliyan¹, Mina Tajvidi²

¹Industrial Engineering Department, Malek Ashtar University of Technology, Tehran, Iran
²Radiotherapy and Oncology Department, Isfahan University of Medical Science, Tehran, Iran

Email address:
atashgar@iust.ac.ir (K. Atashgar)
*Corresponding author

To cite this article:
Karim Atashgar, Ayeh Sheikhaliyan, Mina Tajvidi. A Survival Analysis of Invasive Breast Cancer Patients with and Without in Situ Neoplasm. International Journal of Systems Science and Applied Mathematics. Vol. 3, No. 2, 2018, pp. 30-36.
doi: 10.11648/j.ijssam.20180302.13

Received: June 7, 2018; Accepted: June 25, 2018; Published: July 17, 2018

Abstract: In situ neoplasm (or Carcinoma in situ (CIS)) is expression of malignant epithelial cells. This flat lesion is referred to as ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Considering neoplasm leads one to an effectiveness survival analysis compared to the case that neoplasm is not attended. The objective of this research is to analyze statistically survival of invasive breast cancer patients considering 1) with in situ neoplasm, and 2) without in situ neoplasm, and providing a comparative analysis. This study attempts to reveal that the both medical history (such as diabetes, hypertension, and internal glands disorders such as hypo- and hyperthyroidism) and extra capsular extension play important roles in the hazard function of a patient’s survival analysis. This statistical study indicates that 1) the survival rate of breast cancer patients with in situ neoplasm is more than one who is not initially supported by invasive carcinoma, and 2) in the case of existence of the both in situ neoplasm and invasive malignancy, after the 4th year, the life expectancy is increased compared to the one with only invasive malignant. The statistical analysis indicates that pathology type is recognized as a high hazard factor for a breast cancer patient.

Keywords: Survival Analysis, Invasive Breast Cancer, In Situ Neoplasm, Cox Regression

1. Introduction

Neoplasm can be categorized into two main branches: 1) invasive, and 2) non-invasive. In situ neoplasm is referred to as the abnormal growth of tissue. In this case the abnormal growth is limited to the ducts and lobules and it does not spread to the surrounding tissues. This condition is also known as ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), respectively.

Literature addresses that different researchers have been contributed to the survival analysis of breast cancer patients. Movahedi et al. [1] proposed age, sex, pathology type, and geographic location as the main variables that are capable of effecting on the patients’ survival analysis. Movahedi et al. [1] estimated rate of survival for breast cancer patients based on geographical region. Anwar et al. [2] focused on lobular carcinoma patients and analyzed the related information of this patient type. Anwar et al. [2] considered surgery therapy method, and the rate of local recurrence to analyze the survival of these patients. Bane [3] also studied patients with DCIS type regarding the grade of malignancy. Bane [3] emphasized the importance of diagnosis of DCIS provided by a pathologist. Virnig et al. [4], and Hajilou et al. [5] reviewed treatment of DCIS patients’ literature. Narod et al. [6] estimated morality rate of breast cancer patients after diagnosing DCIS. They discussed that the most important factors corresponding to the high risk conditions are: 1) age at the time of diagnosis, and 2) skin color (white and black). Borgquist et al. [7] focused on the role of epidermal growth factor (Her2) on ductal carcinoma in situ. They concluded that Her2+ leads to decrease cancer recurrence as well as conversion of CIS to the invasive breast cancer type. Margolese et al. [8] evaluated hormone therapy drugs and its impact on menopausal women who has DCIS. Margolese et al. [8] studied only the women
who have been treated by lumpectomy surgery and radiotherapy. Atashgar et al. [9] analyzed survival model of the breast cancer patient with chronic diseases. The statistical analysis of the data indicated that chronic diseases can significantly affect the survival probability in breast cancer. As shown in table 1, although several survival models have been reported for breast cancer patients, literature indicates that the existence of in situ neoplasm effects for the case of invasive breast cancer have not been considered. A comprehensive comparative study of survival for invasive breast cancer with and without in situ neoplasm is capable of effecting the protocol of therapy.

Lobular carcinoma in situ (LCIS) is caused by unusual cells in lobules of a breast and not spread out of the basement membrane. This kind of cancer is rather rare and is more in women in the age range of 40-50 years old, but its manifestation is increasing in menopausal women [15]. Ductal carcinoma in situ (DCIS) condition has potential of converting to the invasive form [16, 17]. Literature addresses that 20-50 percent of DCIS is affected by invasive breast cancer [18-20]. Decision about how to treat a breast cancer patient after surgery is contingent on the accuracy of estimating the behavior and outcome of the disease [21]. Patients who are affected by ductal carcinoma in situ have more possibility of affliction with malignancy compared to the normal population [22]. The conversion of ductal carcinoma in situ to invasive type is a key progression of a breast cancer [23, 24]. This research leads specialists to analyze effectively survival rate of patients’ invasive breast cancer in the condition with in situ neoplasm and compare the survival of this patient type with the case of the patients without in situ neoplasm. In this comprehensive research, tissue and the pathology type of these patient types are also investigated.

| Table 1. Effective factors on breast cancer survival analysis. |
|---|
| **Survival Factors** | Gender | Race | Age | Familial History | Parity | Place of residence | Breast density | Tumor size |
| Virnig et al. (4) | * | * | * | * | * | * | * |
| Anwar et al. (2) | * | * | * | * | * | * | * |
| Anet et al. (10) | * | * | * | * | * | * | * |
| Colzani Et al. (11) | * | * | * | * | * | * | * |
| Movahedi et al. (1) | * | * | * | * | * | * | * |
| Faradmal et al. (12) | * | * | * | * | * | * | * |
| Bane et al. (3) | * | * | * | * | * | * | * |
| Abadi et al. (13) | * | * | * | * | * | * | * |
| Narod et al. (6) | * | * | * | * | * | * | * |
| Borgquist et al. (7) | * | * | * | * | * | * | * |
| Elshof et al. (14) | * | * | * | * | * | * | * |
| **Survival Factors** | No. Lymphnodes | Margins | BMI | Grade | Stage | Pathology | Estrogen status | Progesterone status |
| Virnig et al. (4) | * | * | * | * | * | * | * |
| Anwar et al. (2) | * | * | * | * | * | * | * |
| Anet et al. (10) | * | * | * | * | * | * | * |
| Colzani Et al. (11) | * | * | * | * | * | * | * |
| Movahedi et al. (1) | * | * | * | * | * | * | * |
| Faradmal et al. (12) | * | * | * | * | * | * | * |
| Bane et al. (3) | * | * | * | * | * | * | * |
| Abadi et al. (13) | * | * | * | * | * | * | * |
| Narod et al. (6) | * | * | * | * | * | * | * |
| Borgquist et al. (7) | * | * | * | * | * | * | * |
| Elshof et al. (14) | * | * | * | * | * | * | * |

| **Survival Factors** | Mammography | Type of surgery | Hormonotherapy | Chemoprevention | Adj. Chemotherapy | Adj. Radiotherapy |
| Virnig et al. (4) | * | * | * | * | * | * |
| Anwar et al. (2) | * | * | * | * | * | * |
| Anet et al. (10) | * | * | * | * | * | * |
| Colzani Et al. (11) | * | * | * | * | * | * |
| Movahedi et al. (1) | * | * | * | * | * | * |
| Faradmal et al. (12) | * | * | * | * | * | * |
| Bane et al. (3) | * | * | * | * | * | * |
| Abadi et al. (13) | * | * | * | * | * | * |
| Narod et al. (6) | * | * | * | * | * | * |
| Borgquist et al. (7) | * | * | * | * | * | * |
| Elshof et al. (14) | * | * | * | * | * | * |
2. Methods

In this research 1822 data files of the breast cancer patients who were referred to three breast cancer hospitals of Tehran in the period time of 2007 till mid 2016 are studied. The total number of the patients that referred to these hospitals originally is 2010 patients, but the incompletion of data led the number of the patients that referred to these hospitals the period time of 2007 till mid 2016 are studied. The total who were referred to three breast cancer hospitals of Tehran in Chemotherapy, and 27) Status of the patients' survival, were of metastasis, 24) Type of pathology, 25) Radiotherapy, 26) Grade, 21) Metastasis, 22) Hormone therapy, 23) Number receptor, 17) Stage, 18) Sentinel node status, 19) Tumor size, 20) Familial History, 8) Lymph nodes involvement, 9) Breast site, 4) Level of education, 5) Medical History, 6) Nipple-Skin Involvement, 7) all the patients, including 1) Age, 2) Job, 3) Ethnic, 4) Level of education, 5) Medical History, 6) Nipple-Skin Involvement, 7) Familial History, 8) Lymph nodes involvement, 9) Breast site, 10) Number of involved lymph nodes, 11) Her2 receptor, 12) Extra capsular extension, 13) Vascular-perineural invasion, 14) Estrogen receptor, 15) Type of surgery, 16) Progesterone receptor, 17) Stage, 18) Sentinel node status, 19) Tumor size, 20) Grade, 21) Metastasis, 22) Hormone therapy, 23) Number of metastasis, 24) Type of pathology, 25) Radiotherapy, 26) Chemotherapy, and 27) Status of the patients’ survival, were completely recorded. Table 2 shows the detail data of each of these prognosis factors. The prediction of outcomes based on a set of prognostic factors is a longstanding topic of interest in biostatistics [25].

In this research Kaplan- Meier diagram and Cox proportional hazards models are used to analyze the data of the 1822 patients. Literature indicates that Cox as a semi-parametric model has been used by different researchers for survival analysis of patients. Although Cox considers no assumptions related to hazard initially, it provides the same results that parametric models are capable of providing. On the other hand, Cox is the most applicative model for the case that right censored data are exists. The basic assumption of this model is referred to as the constancy of hazard proportion of groups over the time [26]. The advantages of Cox regression lead researchers to prefer this approach compared to the parametric ones [27].

Response variable of this research is referred to as the patient survival time (in month). This time includes the interval time of finishing the treatment process until the investigation time of this study. The status of each breast cancer patient (dead or alive) is addressed in this interval time by the database of this research. In the case that the status of a patient is not clear, the data is assumed as a censored data.

| Row | Parameter       | No. | Percent | Row | Parameter       | No. | Percent |
|-----|-----------------|-----|---------|-----|-----------------|-----|---------|
| 1   | Age             |     |         | 2   | Job             |     |         |
| 3   | Ethnic          |     |         | 4   | Education       |     |         |
| 5   | Medical History |     |         | 6   | Nipple-Skin Involvement | |         |
| 7   | Familial History|     |         | 8   | Lymph Node Involvement | |         |
| 9   | Breast Site     |     |         | 10  | Number of Lymph Node Involvement | |         |
| 11  | Her2 Receptor   |     |         | 12  | Extra capsular  |     |         |
| 13  | Vascular-perineural Invasion | |         | 14  | Estrogen Receptor |     |         |
| 15  | Surgery         |     |         | 16  | Progesterone Receptor | |         |
| 17  | Stage           |     |         | 18  | Sentinel Node Involvement | |         |
| 19  | Tumor Size      |     |         | 20  | Grade           |     |         |
| 21  | Metastasis      |     |         | 22  | Hormone therapy |     |         |
| 23  | No. Metastasis  |     |         | 24  | Pathology       |     |         |

Table 2. The frequency distribution of characteristics of patients with breast cancer.
3. Results

This comprehensive analysis of breast cancers’ data indicates that:

1. The lowest and the highest age for these patients are addressed by 23 and 93 years old, respectively.
2. Out of these patients, 923 individuals are more than 50 years old, so that 128 individuals of these patients (about 18 percent) unfortunately died before the completion of this research. The classification indicates that 897 individuals are less than 50 years old, so that 75 patients (about 11 percent) unfortunately died before the completion of this research.
3. Pathology type of 91 percent of the studied patients is ductal carcinoma (in situ and invasive), 5.6 percent is lobular carcinoma (in situ and invasive), and 3.4 percent is categorized in other types (such as Paget).

Atashgar et al. [21] analyzed survival model of the breast cancer patient without considering neoplasm. Table 4 addresses a survival Cox model of this research based on the approach of Atashgar et al. [21], while Table 5 indicates a survival Cox model of this research considering neoplasm. In another word, Table 4 shows the results of this research in the case that this research follows the survival approach proposed by Atashgar et al. [21]. Considering neoplasm of Table 5 leads to some new factors that affect the survival model significantly. Although the model based on neoplasm consideration removes tumor size factor, the consideration conveys some important factors including pathology, extra capsular, medical history, and education. The model of Movahedi et al. [1] also considered pathology without existing of tumor size. The analysis leads that the Akaike information criteria (AIC) corresponding to Tables 4 and 5 are 1102.62 and 773.85, respectively. AIC addresses the relative quality of models for a given data set statistically. This analysis indicates that consideration of neoplasm in this research allows performing a better survival model compared to the survival model approached by Atashgar et al. [21].

### Table 3. The Survival probability of patients considering Pathology type.

| Kind Of Pathology | Survival probability (in year) |
|-------------------|--------------------------------|
|                   | 1    | 2    | 3    | 4    | 5    | 6    | 7    | 8    | 9    |
| Carcinoma In situ | 100% | 100% | 91.66% | -   | -   | -   | -   | -   | -   |
| Carcinoma Invasive| 95.61% | 91.16% | 84.55% | 75.32% | 73.02% | 71.57% | 56.92% | 50%  | 19.35% |
| Carcinoma In situ-Invasive| 96.83% | 93.45% | 90.03% | 78.20% | 74.92% | 72.86% | 61.96% | 57.22% | 22.22% |
| All               | 96.25% | 90.10% | 86.22% | 78%   | 74.15% | 72.33% | 68%   | 66.56% | 18.51% |

### Table 4. The Results of the Cox Proportional Hazard Model approaching atashgar et al. [21].

| Parameter            | β     | SE    | Sig  | HR (95% CI)     |
|----------------------|-------|-------|------|-----------------|
| Age                  | 0.071 | 0.01  | 0    | 1.074           |
| Tumor Size           | 0.015 | 0.032 | 0    | 1.122           |
| Metastasis           | 1.882 | 0.211 | 0    | 6.565           |
| Hormone therapy      | -0.708 | 0.152 | 0    | 0.493           |

### Table 5. The Results of the Cox Proportional Hazard Model considering neoplasm factor.

| Parameter             | β     | SE    | Sig  | HR (95% CI)     |
|-----------------------|-------|-------|------|-----------------|
| Age                   | 0.858 | 0.268 | 0.001| 2.36            |
| Medical History       | -1.219 | 0.353 | 0.001| 0.29            |
| Pathology             | -0.186 | 0.306 | 0.545| 0.83            |
| Number of lymph Node  | 0.115 | 0.045 | 0.011| 1.12            |
| Extra capsular extension | 0.839 | 0.432 | 0.037| 2.31            |
| Metastasis            | 1.299 | 1.272 | 0.046| 3.66            |
In this study, to analyze the impact of explanatory variables on breast cancer patients’ survival, semi parametric Cox regression is used. Stepwise approach is also used to design an adequate regression model assuming α=0.05. Table 5 indicates that variables including 1) patient age, 2) Medical history, 3) number of involved lymph nodes, 4) extra capsular extension, and 5) metastasis significantly impact on the analysis of a breast cancer patient’s survival. Although Table 5 shows that pathology type is not a significant variable under consideration of α=0.1, analysis of Kaplan-Meier graph (Figure 1) leads one to a remarkable influence of neoplasms as well as survival calculations on patients (Table 3). In other words, neglecting pathology type is capable of leading analysis of the patients with in situ neoplasm to a significant error. Hence pathology type is allowed to evaluate as a significant variable. The conclusion allows us to place the pathology factor in the proposed survival model of this study.

4. Discussion

Usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH)/low-grade ductal carcinoma in situ (LG-DCIS) are biologically distinct, intraductal, epithelial proliferations with different clinical implications. Usual ductal hyperplasia can even contain apocrine metaplastic cells [28]. Ductal carcinoma in situ (DCIS) is a risk factor for incomplete resection of breast cancer. Detecting DCIS around breast cancer before treatment may therefore alter surgery [29] Wu et al. [30] also considered the Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast. Literature indicates that about 30 percent of ductal carcinoma in situ lesions during a certain time become invasive breast cancer [19]. Ductal carcinoma in situ treatment with a combination of surgery, radiotherapy, and hormone therapy prevents local recurrence for 10-15 percent of the patients; however 50 percent of cases become invasive breast cancer [31-33]. Due to abnormal behavior of carcinoma in situ, it is recommended that CIS should be detected at earlier stage. Conversion of CIS to invasive case is a key occurrence. This comprehensive research using statistical analysis proposed a survival model considering pathology type. The analysis of this research indicates that breast cancer patients with in situ neoplasms (without regarding the stage of disease) are placed in a higher survival rate compared to the patient type who refers to a therapeutic center initially with invasive carcinoma. The higher rate is due to tendency of recurrence for an invasive case without in situ neoplasm. Where the rate of this case is more compared to a breast cancer patient with a diagnosed in situ neoplasm. The analysis of Kaplan-Meier diagram (Figure 1) also indicates that diagnosis of in situ neoplasm before invasive malignancy increases longevity after the 4th year than a case with only the invasive malignancy. The statistical analysis indicated that pathology type (with a relative hazard of 0.831) is recognized as a high hazard factor for breast cancer patients. This means that a patient who refers initially with invasive carcinoma have 0.831 fold more hazard of death compared to an invasive breast cancer with neoplasm that diagnosed with in situ. Hence timely diagnosis of carcinoma in situ not only thereby increasing the chance of patient lifetime, but also the timely diagnosis remarkably improves the mental status of a breast cancer patient.

5. Conclusion

This research focused on analyzing statistically survival of invasive breast cancer patients considering with in situ neoplasm, and without in situ neoplasm conditions. The results of this research revealed that the both medical history and extra capsular extension play important roles in the hazard function of a patient’s survival analysis. The statistical analysis of this study indicated that 1) the survival rate of
breast cancer patients with in situ neoplasm is more than one who is not initially supported by invasive carcinoma, and 2) in the case of existence of the both in situ neoplasm and invasive malignancy, after the 4th year, the life expectancy is increased compared to the one with only invasive malignant. The statistical analysis indicated that pathology type is recognized as a high hazard factor for a breast cancer patient. The proposed model of this research also addressed that age is evaluated as one of the most important hazard factor. It indicates that death hazard for patients with the age of more than 50 years old are increased by about 2.35 times. This research also addressed that the survival rate of breast cancer patients for the first year is 96.25%. This result is close to the estimation for the 3 years for breast cancer patients are 86.22% and 74.15%, survival of the 5 years for hormone therapy have a significant role in the proposed model.

Statistical analysis of this study shows that in addition the age at the time of diagnosis, some factors including education, morbidity, and treatment have a significant role in the proposed model clearly.

References

[1] Movahedi M, Haghighat SH, Khayamzadeh M, Moradi A, Ghanbari-Motlagh M, Mirzaei H, Akbari ME. Survival Rate of Breast Cancer Based on Geographical Variation in Iran, a National Study. Iranian Red Crescent Medical Journal 2012; 14 (12): 798-804.

[2] Anwar a I, Down S K, Rizvi S, Farooq N, Burger A, Morgan A, Hussien M. I. Invasive lobular carcinoma of the breast: Should this be regarded as a chronic disease? International Journal of Surgery 2010; (8): 346-352.

[3] Bane A. Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why”. International Journal of Breast Cancer 2013: 1-7.

[4] Virmig B. A, Tuttle T. M., Kane R. L. Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. Journal of the National Cancer Institute 2010; 102: 170–178.

[5] Hajilou M, Alizadeh Otaghvar H. R, Mirmalek S. A, Yoosefi F, Khazrayi S, Tahery N, Jafari M. Ductal Carcinoma In situ Breast: A Review Article, Iranian Journal of Surgery 2013; 21(1).

[6] Narod S. A, Iqbal J., Giannakeas V., Sopik V., Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. Journal of the American Medical Association Oncology 2015; 1 (7): 888-896.

[7] Borgquist S, Zhou W, Irström K, Amini R, Sollice T, Solrice T, Blomqvist C, Butt S, Wärnberg F. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. Bio Medical Central Cancer 2015; 15: 1-10.

[8] Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PWF, Cianfrocca ME, Brufsky AM, Gross HM, Sooij GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancent 2016; 367(10021): 849- 856.

[9] Atashgar K, Sheikhaliyani A, Tajvidi M, Molana S H, Jalaeian L. Survival Analysis of Breast Cancer Patients with Different Chronic Diseases Using Parametric and Semi-Parametric Approaches. Multidisciplinary Cancer Investigation 2018; 2(1): 26-32.

[10] Anet G A, Nestor A M O. Application of hazard models for patients with breast cancer in Cuba. International Journal of Clinical and Experimental Medicine 2011; 4(2): 148-156.

[11] Colzani E, Liljegren A, Johansson AL, V, Adolfsson J, Hellborg H, Hall P, L, Czene K. Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics. Journal of Clinical Oncology 2011; 29(30): 4014-4021.

[12] Fardmal J, Mafi M, Sadighi-Pashaki A, Karami M, Roshanaei GH. Factors Affecting Survival in Breast Cancer Patients Referred to the Darol Aitam-e Mahdieh Center. Journal of Zanjan University of Medical Sciences 2014; 22: 105-115.

[13] Abadi A, Yavari P, Dehghani-Arani M, Alavi-Majd H, Ghasemi E, Amanpour F, Bajdik C. Cox Models Survival Analysis Based on Breast Cancer Treatments. Iranian Journal of Cancer Prevention 2014; 7(3): 124-129.

[14] Elshof L E, Schaaepveld M, Schmidt M K, Rutgers E J, van Leeuwen F E, Wesseling J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Research Treaty 2016; 159: 553-563.

[15] Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prevention 2005; 14(4): 1008–1011.

[16] Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saksin R, Spaye J, Taylor C, Paszat L. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer 2012; 106(6):1160-1165.

[17] Usmani S, Khan HA, Al Saleh N, abu Huda F, Marafi F, Amanguno HG, Al Nafisi N, Al Kandari F. Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast, Nuclear medicine communication 2011; 32(11): 1084-1087.

[18] Page, D. L., Dupont, W. D., Rogers, L. W., Jensen, R. A., Schuyler, P. A. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-1200.

[19] Page D. L., Dupont W. D., Rogers L. W., and Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982; 49(4): 751–758.

[20] Sanders, M. E., Schuyler, P. A., Dupont, W. D., Page, D. L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103: 2481-2484.
[21] Atashgar K, Molana S. H, Biglarian A. Sheikhaliyan A. Analysis of Survival Data of Patient with Breast Cancer Using Cox Regression Model. Iranian Journal of Surgery 2016; 24(1): 62-76.

[22] Choi HK, Cho N, Moon WK, Im SA, Han W, Noh DY. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. European Journal of Radiology 2012; 81(4): 737-43.

[23] Volinia S., Galasso M., Sana ME., Wise TF., Palatini J., Huebner K., Croce CM. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proceedings of the National Academy of Sciences of the United States of America 2012; 109(8): 3024-3029.

[24] Zhao X, Mirza S, Alshareeda A, Zhang Y, Gurumurthy CB, Bele A, Kim JH, Mohibi S, Goswami M, Lele SM, West W, Qiu F, Ellis IO, Rakha EA, Green AR, Band H, Band V. Overexpression of a novel cell cycle regulator eddysonless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. Breast Cancer Research and Treatment 2012.

[25] Klein J, Moeschberger M. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer 2005.

[26] Atashgar K, Sheikhaliyan A, Biglarian A. Reviewing and Analyzing Breast Cancer Survival Models. Iranian Journal of Surgery 2016; 24(3): 1-16.

[27] Daugherty EC., Daugherty MR., Bogart JA, Shapiro A. Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor Negative Breast Cancer: Clinical Breast Cancer 2016; 16(6): 500-506.

[28] Peng Y, Butt M B, Chen B, Zhang X, Tang P. Update on Immunohistochemical Analysis in Breast Lesions. Archives of Pathology & Laboratory Medicine Online 2017; 141(8):1033-1051.

[29] Knuttel, Floortje M.; van der Velden, Bas H. M.; Loo, Claudette E. Prediction Model For Extensive Ductal Carcinoma In Situ Around Early-Stage Invasive Breast Cancer. Investigative Radiology 2016; 51(7):462-468.

[30] Wu SG, Zhang WW, Sun JY, He ZY. Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. Cancer Management and Research 2018; 10: 527-534.

[31] Fisher B., Land S., Mamounas E., Dignam J., Fisher E. R., and Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in Oncology, August 2001, 28(4): 400–418.

[32] Julien P, Bijkner N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. The Lancet 2000; 355(9203): 528–533.

[33] N. Bijker, P. Meijnen, J. L. Peterse et al., “Breast-conserving treatment with or without radiotherapy in ductal carcinoma-insitu: ten-year results of european organisation for research and treatment of cancer randomized phase III trial 10853—a study by the EORTC breast cancer cooperative group and EORTC radiotherapy group. Journal of Clinical Oncology 2006; 24(21): 3381–3387.

[34] Ivanauskienë R, Gedminaitë J, Juozaitytë E, Vanagas G, Šimoliūnienë R, Padaiga. Survival of women with breast cancer in kaunas region, Lithuania. Medicina (Kaunas) 2011; 48: 272-276.

[35] Gohari MR, Khodabakhshi R, Shahidi J, Moghadami Fard Z, Foadzi H, Soleimani F, Biglarian A. The impact of multiple recurrences in disease-free survival of breast cancer: an extended Cox model. Tumori 2012; 98: 428-33.

[36] Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer 2015; 15(2): 153-160.